Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02445248
Title Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients (JULIET)
Acronym JULIET
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | ITA | FRA | DEU | CAN | AUT | AUS

Facility Status City State Zip Country Details
UCSF Medical Center . San Francisco California 94143 United States Details
Emory University School of Medicine SC CTL019 Atlanta Georgia 30322 United States Details
University of Chicago Medical Center Hematology and Oncology SC - CTL019B2207J Chicago Illinois 60637 United States Details
University of Kansas Cancer Center SC - CTL019C2201 Westwood Kansas 66205 United States Details
Sidney Kimmel Comprehensive Cancer Center SC-2 Baltimore Maryland 21287-0013 United States Details
Uni of Michigan Health System SC CTL019 Ann Arbor Michigan 48109 United States Details
University of Minnesota Minneapolis Minnesota 55455 United States Details
Weill Cornell Medical College New York New York 10065 United States Details
The Ohio State University James Cancer Hospital & Columbus Ohio 43210 United States Details
Oregon Health and Science Univ Oregon Health & Sci Uni Portland Oregon 97239 United States Details
University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania 19104 United States Details
MD Anderson Cancer Center SC Houston Texas 77030 United States Details
Novartis Investigative Site Melbourne Victoria 3000 Australia Details
Novartis Investigative Site Camperdown NSW Australia Details
Novartis Investigative Site Vienna A-1090 Austria Details
Novartis Investigative Site Hamilton Ontario L8V 5C2 Canada Details
Novartis Investigative Site Montreal Quebec H1T 2M4 Canada Details
Novartis Investigative Site Pierre Benite 69495 France Details
Novartis Investigative Site Koeln Nordrhein-Westfalen 50937 Germany Details
Novartis Investigative Site Wuerzburg 97080 Germany Details
Novartis Investigative Site Milano MI 20133 Italy Details
Novartis Investigative Site Fukuoka city Fukuoka 812-8582 Japan Details
Novartis Investigative Site Sapporo city Hokkaido 060 8648 Japan Details
Novartis Investigative Site Chuo ku Tokyo 104 0045 Japan Details
Novartis Investigative Site Amsterdam 1105 AZ Netherlands Details
Novartis Investigative Site Oslo NO 0424 Norway Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field